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The United Nations sustainable development goals have led to the development of global 
plans to end the tuberculosis (TB) epidemic. Individuals with latent tuberculosis infection 
(LTBI) are at risk of reactivation disease and onward transmission to their contacts; prompt 
identification of these persons before they develop infectious TB will therefore help to 
control the epidemic. Unfortunately, there is no gold standard test for LTBI diagnosis and 
existing tests have uniformly poor ability to predict which individuals will go on to develop 
active TB.  Currently used tests are the tuberculin skin test (TST), which is relatively cheap 
and simple to administer in the field but can be falsely positive in people who are BCG-
vaccinated or exposed to non-tuberculous mycobacteria1, and interferon gamma release 
assays (IGRAs), which are more specific but are costly and require specialist laboratory 
processing. 
 
In The Lancet Respiratory Medicine, Morten Ruhwald and colleagues2 report an assessment 
of C-Tb (Statens Serum Institut, Copenhagen, Denmark), a diagnostic skin test for latent 
tuberculosis infection. This test is based on the Mycobacterium tuberculosis-specific RD1 
antigens ESAT-6 and CFP10 that are used in IGRAs. C-Tb combines the simplicity of 
administering a skin test without the need for laboratory processing and high specificity 
because of the use of M tuberculosis-specific antigens that are not present in the BCG 
vaccine or most environmental mycobacteria. The authors compared C-Tb with the 
QuantiFERON TB Gold In-Tube (QFT) IGRA and the TST in 979 people separated into 
subgroups of varying degrees of risk of infection with M tuberculosis, ranging from people 
with no known history of exposure to tuberculosis (n=263), to occasional contacts (n=299) 
and close contacts (n=316) of people with tuberculosis, to patients with culture-confirmed 
tuberculosis (n=101), as has been used previously to assess IGRAs.3 All participants older 
than 5 years were tested with QFT. People were then randomised to be tested with the TST 
in the left arm and C-Tb in the right arm or vice versa or, in a small subgroup, C-Tb alone to 
test for an interaction with the TST. A trend was found towards positivity with increasing 
risk of infection, with concordant results seen between C-Tb and QFT in 785 (94%) of 834 
participants. C-Tb, however, was classified as positive in fewer patients with tuberculosis 
than was QFT (68 [67%] vs 82 [81%], p=0.003). The overall safety profiles of C-Tb and TST 
were similar, although injection-site pain and haematoma were seen more often with C-Tb 
than with the TST (14% vs 2%). 
 
Current World Health Organization recommendations encourage testing and treatment of 
contacts of pulmonary TB patients as well as individuals with various forms of 
immunosuppression, including HIV in low incidence countries, while treatment without 
testing is an option for children under 5 years in contact with infectious TB and for HIV 
infected individuals in high burden countries4. The high levels of concordance between C-Tb 
and QFT and the ease of administration of C-Tb raises the prospect that the new test could 
be used at the point of care to diagnose LTBI with increased specificity, thus reducing the 
number of uninfected people who receive unnecessary treatment with the associated risk of 
adverse events such as hepatotoxicity 5. 
2 
 
 
While differences between the TST and IGRA can be attributed to BCG and non-tuberculous 
mycobacteria sensitisation, the reason for, and clinical significance of, discordant results 
between the commercial ELISA and ELISPOT versions of IGRAs remain unclear. Similarly, the 
reasons for discordance between C-Tb and QFT are unclear. The different route of 
administration between the blood based IGRA and the skin based C-Tb may explain some of 
the observed difference. While further research is needed to understand the difference, this 
modest level of discordance should not affect the practical application of the test. The lower 
sensitivity of C-Tb among TB patients relative to QFT suggests a better ability of the blood 
assay to measure the presence of interferon gamma. By contrast, a previously published 
study of C-Tb by the same investigators showed a comparable level of sensitivity between C-
Tb and QFT in 273 recently diagnosed active TB patients (73.9% (95% CI 67.8–79.3%) for C-
Tb versus 75.1% (95% CI 69.3–80.2%) for QFT) 6.   
 
Ultimately, a major aim of tests for LTBI is to identify individuals at the highest risk of 
progressing to active TB. A systematic review and meta-analysis reported that the relative 
risk of developing active TB among IGRA positive individuals compared to negative persons 
was weak to moderate (about 2–3)6. It is unlikely that those with a positive C-Tb test will 
have a higher chance of progressing to active TB compared to those with a positive IGRA, as 
the tests use the same antigens. A further limitation of a skin test is the requirement for a 
return visit to read the size of the induration. Innovative healthcare delivery methods 
utilising new technologies could allow reading of the skin test immune response without 
direct healthcare contact, reducing loss to follow-up and encouraging appropriate 
treatment where necessary. 
 
Ruhwald and colleagues found a higher level of injection site haematomas with C-Tb 
compared to TST (14% vs. 2%). While this is not a serious adverse event, further data from 
larger studies are needed to confirm whether there is an increased risk of haematomas in 
post marketing surveillance.  
 
C-Tb potentially provides an upgrade to the diagnosis of LTBI by combining the specificity of 
IGRA with the logistical simplicity of TST. Further research into operational, economic and 
predictive aspects of C-Tb, including cost-effectiveness and acceptability, will allow a fuller 
assessment of its potential use in TB control programmes in different epidemiological 
settings – for example, in settings with different burdens of TB, HIV and co-morbidities. In 
the meantime, the search for a highly predictive assay for LTBI continues.  
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